You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
The company's technology uses CRISPR to deplete unwanted nucleic acid sequences from NGS libraries, leaving behind targets of interest.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.
The GTEx Consortium, which has been working for 10 years, analyzed how genetic variants affect gene regulation, and how this contributes to disease and traits.
The panel also said that if any nation does decide to allow germline genome editing, its use should be limited to preventing serious monogenic diseases.
The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.
The company has taken an exclusive license to the Casɸ proteins and is working to characterize their capabilities to determine how they can best be used.
The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.